laboratoire commun CEA/DRF — spiral2 — CNRS/IN2P3

PhD position in nuclear instrumentation

Dosimetry for *in vitro* assessment of targeted alpha therapy

Targeted alpha therapy (TAT) is a treatment modality in which a labelled α-emitting radioisotope is injected to the patient. The labelled molecules specifically target biomarkers of the tumour cells. Consequently, the dose deposition, produced by the radioisotopes decay is concentrated at a close distance of tumour cells, especially in the case of α-emitters. The favourable characteristics of α particles (short range, high linear energy transfer, potent cytotoxicity), explain the increasing development and use of TAT [1].

As any new treatment, TAT requires preclinical investigations to evaluate the efficiency of new molecules and compare the results to other existing modalities. *In vitro* experiments are part of these investigations. They consist in exposing cells cultured in a dish to labelled radioisotopes diluted in culture medium. In this kind of experiments, biological effects (such as survival fraction for example) are usually compared to the injected activity. Even if this is relevant for β-emitters (due to the millimetre range of β-particles), it is not adapted to the quantitative evaluation of α-emitting radioisotopes. Moreover, to compare the efficiency of TAT to other treatments such as external beam radiotherapy or β-emitting targeted radiotherapy [2], the knowledge of the absorbed dose in cells is much more relevant. The determination of this quantity is given by the MIRD formalism [3-5] and, in the case of *in vitro* experiments, depends on the spatial distribution of the radioisotopes in the culture medium and the thickness of the cells.

An innovative method has been successfully tested during a preclinical evaluation of ^{212}Pb-VCAM-1 [6] to provide reliable and accurate dose measurements during *in vitro* experiments [7]. This method primarily relies on the measurement of the energy spectrum of α-particles emitted from the culture medium trough a 2.5 µm mylar wall by silicon detectors. The deconvolution of the experimental spectrum using Monte Carlo simulations provides the spatial distribution of the radioisotopes in the culture medium that is necessary for the dose determination.

The goal of this PhD thesis is to implement and characterise a dosimetry prototype adapted to *in vitro* experiments.

The prototype implementation will be based on silicon detectors of appropriate surface (determined by cell culture constraints) and thickness (determined by α particles range), charge preamplifiers and a FASTER acquisition system. Customized culture wells will have to be designed to be compatible with the detection of α-particles (mylar base of µm thickness).

The whole detection system will have to be light-shielded due to the use of the silicon detector and compatible with biology experimental conditions (principally temperature, humidity and oxygen concentration stabilization).

Once the prototype implemented, its geometry will be reproduced in Monte Carlo simulations to determine its response function with different source geometries and energy spectra. These simulations will allow testing and optimizing different deconvolution methods to determine the isotopes spatial distribution of experimental setups and the dose deposition in cells.

Finally, the prototype and the deconvolution methods will be experimentally evaluated with ascertainable spatial distribution provided by α sources and customized attenuators.

Ideally, after validation of the system, *in vitro* dosimetry will be performed with cells exposed to different activities of labelled radioisotopes added to the culture medium and compared to the biological effects.

This project will be done at GANIL, in the framework of the research program on the production of innovative medical radioisotopes funded by ANR (REPARE project). GANIL has also important skills in nuclear instrumentation and preclinical dosimetry [8-13] and already developed collaborations with other laboratories (LPC Caen, Cyceron, ISTCT…) in interdisciplinary domains.

Expected skills:
The student must have a background in nuclear physics with a good knowledge of the detection of radiations and their interactions with matter. Knowledge in radiotherapy and dosimetry would be a plus.
The student will participate to the prototype implementation. He/she will perform experimental characterizations and evaluations as well as Monte Carlo simulations and data analysis. The candidate must thus have an interest for experimentation as well as simulation and will have to develop skill in instrumentation, programming and Monte Carlo simulations.
The candidate will need to be able to work in an interdisciplinary domain with people from other research fields such as biology, medical physics or medicine.

Contact: Anne-Marie Frelin
GANIL, BP 55027, 14076 Caen France
Phone: +33 (0)2 31 45 45 30
mail: anne-marie.frelin_at_ganil.fr

References:

[1] F. Guerard, J. Barbet, J.-F. Chatal, F. Kraeber-Bodere, M. Cherel and F. Haddad, "Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy," *Q J Nucl Med Mol Imaging,* vol. 59, pp. 161-167, 2015.

[2] N. Falzone, N. L. Ackerman, L. de la Fuente Rosales, M. A. Bernal, X. Liu, S. G. Peeters, M. S. Soto, A. Corroyer-Dulmont, M. Bernaudin, E. Grimoin, O. Touzani, N. R. Sibson and K. A. Vallis, "Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases," *Theranostics 2018,* vol. 8, no. 1, pp. 292-303, 2018.

[3] W. E. Bolch, K. F. Eckerman, G. Sgouros and S. R. Thomas, "MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature," *J Nucl Med,* vol. 50, no. 3, pp. 477-84, 2009.

[4] C.-Y. Huang, S. Guatelli, B. M. Oborn and B. J. Allen, "Microdosimetry for targeted alpha therapy of cancer," *Comput Math Methods Med,* vol. 2012, 2012.

[5] M. Šefl, K. Pachnerová Brabcová and V. Štěpán, "Dosimetry as a Catch in Radiobiology Experiments," *Radiat Res,* vol. 190, no. 4, pp. 404-411, 2018.

[6] A. Corroyer-Dulmont, S. Valable, N. Falzone, A.-M. Frelin-Labalme, O. Tietz, J. Toutain, M. Soto, D. Divoux, L. Chazaviel, E. Pérès, N. Sibson, K. Vallis and M. Bernaudin, "Targeted Alpha-particle Therapy for Early Brain Metastases," *currently under revision.*

[7] A.-M. Frelin-Labalme, T. Roger, N. Falzone, B. Q. Lee, N. R. Sibson, K. A. Vallis, S. Valable, M. Bernaudin and A. Corroyer-Dulmont, "Radionuclide spatial distribution and dose deposition for in vitro assessment of targeted alpha therapy," *currently under revision.*

[8] M. O. Frégeau, M. Delarue, A.-M. Frelin-Labalme, B. Laurent, X. Ledoux and C. Varignon, "Light response and efficiency calibration of EJ309 liquid scintillator between 3 and 45 MeV," *NUcl. INst. and Meth. A,* p. 162301, 2019.

[9] C. Le Deroff, A.-M. Frelin-Labalme and X. Ledoux, "Characterization of a scintillating fibre detector for small animal imaging and irradiation dosimetry," *Br J Radiol,* vol. 90, no. 1069, p. 20160454, 2017.

[10] C. Le Deroff, A. Frelin and X. Ledoux, "Energy dependence of a scintillating fiber detector for preclinical dosimetry with an image guided micro-irradiator," *Phys Med Biol,* p. [Epub ahead of print], 2019.

[11] C. Le Deroff, E. Pérès, X. Ledoux, J. Toutain and A.-M. Frelin-Labalme, "In vivo dosimetry with a scintillating fiber dosimeter in preclinical image-guided radiotherapy," *currently under revision.*

[12] A.-M. Frelin-Labalme and V. Beaudouin, "Development of a dynamic phantom and investigation of mobile target imaging and irradiation in preclinical small animal research," *Br. J. Radiol.,* vol. 90, no. 1069, p. 20160442, 2017.

[13] A. Frelin, V. Beaudouin, C. Le Deroff and T. Roger, "Implementation and evaluation of respiratory gating in small animal radiotherapy," *Phys Med Biol,* vol. 63, no. 21, p. 215024, 2018.